Repository logo
 
Publication

Serum Lipids and Prostate Cancer

2021Journal article Open access
Simple item page
dc.contributor.authorGarrido, M
dc.contributor.authorMarta, J
dc.contributor.authorRibeiro, R
dc.contributor.authorCampos Pinheiro, L
dc.contributor.authorGuimarães, J
dc.date.accessioned2022-03-31T12:06:15Z
dc.date.available2022-03-31T12:06:15Z
dc.date.issued2021
dc.description.abstractBackground: Conflicting results are found in the literature relating serum lipids levels and prostate cancer. Some results imply a relationship between them; others contradict this association. The purpose of this study was to investigate a possible association between serum lipids levels and prostate cancer, at time of diagnosis. Methods: We measured serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in 237 patients submitted to a prostate biopsy, with PSA between 2 and 10 ng/ml. Patients without cancer at biopsy were used as controls, and the others were considered as cases. No information about lipid-lowering therapy, including statins, was available neither in cases nor in controls. Cases were divided into risk groups, according to the disease severity, based on staging. Lipids levels were compared between groups, using parametric and nonparametric tests. Logistic regression analysis and odds ratios were calculated. Results: LDL and total cholesterol levels were lower in patients with cancer, with the difference being statistically significant for LDL cholesterol (p = 0.010) and borderline for total cholesterol (p = 0.050). No significant differences were found between the several risk groups. Odds ratios for low LDL cholesterol (<130 mg/dl) and low total cholesterol (<200 mg/dl), with prostate cancer as the outcome, were 1.983 and 1.703, respectively. There were no significant differences between cases and controls for the other lipids. Conclusion: Lower LDL cholesterol (<130 mg/dl) and lower total cholesterol (<200 mg/dl) serum levels seem to associate with prostate cancer, at time of diagnosis.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Clin Lab Anal. 2021 Apr;35(4):e23705.pt_PT
dc.identifier.doi10.1002/jcla.23705.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4030
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.subjectCHLC PAT CLINpt_PT
dc.subjectCHLC UROpt_PT
dc.subjectAgedpt_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectCase-Control Studiespt_PT
dc.subjectHumanspt_PT
dc.subjectCholesterol, LDL / bloodpt_PT
dc.subjectLipids / blood*pt_PT
dc.subjectLogistic Modelspt_PT
dc.subjectOdds Ratiopt_PT
dc.subjectProstatic Neoplasms / blood*pt_PT
dc.subjectRisk Factorspt_PT
dc.subjectTriglycerides / bloodpt_PT
dc.titleSerum Lipids and Prostate Cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPagee23705pt_PT
oaire.citation.titleJournal of Clinical Laboratory Analysispt_PT
oaire.citation.volume35pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Clinical Laboratory Analysis 2021.pdf
Size:
376 KB
Format:
Adobe Portable Document Format
Download

Collections

PAT CLIN - Artigos
URO - Artigos